NOVAVAX INC Diluted Shares Outstanding (Weighted Average)
NOVAVAX INC (NVAX) reported Diluted Shares Outstanding (Weighted Average) of 164.57 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- NOVAVAX INC weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 164.57M shares, a 7.13% decline year-over-year.
- NOVAVAX INC weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 163.28M shares, a 8.08% decline year-over-year.
- NOVAVAX INC weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 187.83M shares, a 17.17% increase year-over-year.
- NOVAVAX INC weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 162.35M shares, a 1.44% increase year-over-year.
- NOVAVAX INC weighted average number of shares outstanding, diluted for fiscal 2025 was 173.10M shares, a 13.74% increase from fiscal 2024.
- NOVAVAX INC weighted average number of shares outstanding, diluted for fiscal 2024 was 152.19M shares, a 51.03% increase from fiscal 2023.
- NOVAVAX INC weighted average number of shares outstanding, diluted for fiscal 2023 was 100.77M shares, a 28.89% increase from fiscal 2022.
- NOVAVAX INC weighted average number of shares outstanding, diluted for fiscal 2022 was 78.18M shares, a 5.08% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 164.57M shares 10-Q · filed 2026-08-06 | 163.93M shares 10-Q · filed 2026-08-06 | 171.89M shares derived: average of 3 quarters · filed 2026-08-06 | 169.51M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 163.28M shares 10-Q · filed 2026-05-06 | 175.55M shares derived: average of 2 quarters · filed 2026-05-06 | 171.15M shares derived: average of 3 quarters · filed 2026-05-06 | 172.67M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 187.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 175.09M shares derived: average of 2 quarters · filed 2026-02-26 | 175.80M shares derived: average of 3 quarters · filed 2026-08-06 | 173.10M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 162.35M shares 10-Q · filed 2025-11-06 | 169.78M shares derived: average of 2 quarters · filed 2026-08-06 | 168.19M shares 10-Q · filed 2025-11-06 | 169.37M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 177.22M shares 10-Q · filed 2026-08-06 | 177.41M shares 10-Q · filed 2026-08-06 | 171.71M shares derived: average of 3 quarters · filed 2026-08-06 | 168.80M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 177.63M shares 10-Q · filed 2026-05-06 | 168.96M shares derived: average of 2 quarters · filed 2026-05-06 | 165.99M shares derived: average of 3 quarters · filed 2026-05-06 | 165.96M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 160.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 160.18M shares derived: average of 2 quarters · filed 2026-02-26 | 162.07M shares derived: average of 3 quarters · filed 2026-02-26 | 152.19M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 160.05M shares 10-Q · filed 2025-11-06 | 162.95M shares derived: average of 2 quarters · filed 2025-11-06 | 149.49M shares 10-Q · filed 2025-11-06 | 147.44M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 165.85M shares 10-Q · filed 2025-08-06 | 145.12M shares 10-Q · filed 2025-08-06 | 143.24M shares derived: average of 3 quarters · filed 2026-02-26 | 133.28M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 139.92M shares 10-Q · filed 2025-05-08 | 131.93M shares derived: average of 2 quarters · filed 2026-02-26 | 122.43M shares derived: average of 3 quarters · filed 2026-02-26 | 117.84M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 123.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 113.68M shares derived: average of 2 quarters · filed 2026-02-26 | 110.48M shares derived: average of 3 quarters · filed 2026-02-26 | 100.77M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 103.43M shares 10-Q · filed 2024-11-12 | 103.75M shares derived: average of 2 quarters · filed 2024-11-12 | 93.05M shares 10-Q · filed 2024-11-12 | 93.37M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 104.06M shares 10-Q · filed 2024-08-08 | 87.77M shares 10-Q · filed 2024-08-08 | 90.02M shares derived: average of 3 quarters · filed 2025-02-27 | 87.08M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 86.16M shares 10-Q · filed 2024-05-10 | 83.00M shares derived: average of 2 quarters · filed 2025-02-27 | 81.42M shares derived: average of 3 quarters · filed 2025-02-27 | 80.60M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 79.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 79.06M shares derived: average of 2 quarters · filed 2025-02-27 | 78.75M shares derived: average of 3 quarters · filed 2025-02-27 | 78.18M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 78.27M shares 10-Q · filed 2023-11-09 | 78.21M shares derived: average of 2 quarters · filed 2023-11-09 | 77.63M shares 10-Q · filed 2023-11-09 | 78.20M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | 78.14M shares 10-Q · filed 2023-08-08 | 77.31M shares 10-Q · filed 2023-08-08 | 78.18M shares derived: average of 3 quarters · filed 2024-02-28 | 77.32M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | 80.71M shares 10-Q · filed 2023-05-09 | 78.20M shares derived: average of 2 quarters · filed 2024-02-28 | 77.05M shares derived: average of 3 quarters · filed 2024-02-28 | 76.31M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | 75.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 75.21M shares derived: average of 2 quarters · filed 2024-02-28 | 74.85M shares derived: average of 3 quarters · filed 2024-02-28 | 74.40M shares 10-K · filed 2024-02-28 |
| 2021-09-30 | 74.75M shares 10-Q · filed 2021-11-05 | 74.43M shares derived: average of 2 quarters · filed 2021-11-05 | 73.97M shares 10-Q · filed 2021-11-05 | 71.92M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 74.12M shares 10-Q · filed 2021-08-05 | 73.58M shares 10-Q · filed 2021-08-05 | 70.98M shares derived: average of 3 quarters · filed 2023-02-28 | 68.62M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 73.03M shares 10-Q · filed 2022-05-10 | 69.41M shares derived: average of 2 quarters · filed 2023-02-28 | 66.79M shares derived: average of 3 quarters · filed 2023-02-28 | 64.75M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 65.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 63.67M shares derived: average of 2 quarters · filed 2023-02-28 | 61.99M shares derived: average of 3 quarters · filed 2023-02-28 | 57.55M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 61.55M shares 10-Q · filed 2021-11-05 | 60.09M shares derived: average of 2 quarters · filed 2021-11-05 | 54.81M shares 10-Q · filed 2021-11-05 | |
| 2020-06-30 | 58.62M shares 10-Q · filed 2021-08-05 | 51.40M shares 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | 24.10M shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |